Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment

Quince Therapeutics, Inc.

Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.
Phase 3 NEAT trial enrolled 61 participants (>50%); topline results expected Q4 2025.
Received FDA Fast Track designation (June 2024); Phase 3 ATTeST results published in The Lancet Neurology.
R&D $18.6M, G&A $17.6M; operating cash burn $31.9M includes $5M milestone and $17.1M goodwill impairment.
Appointed Dr. William Whitehouse to SAB; USPTO allowed patent claims extending to 2036 for eDSP in A-T.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.